Roche files MabThera for new maintenance lymphoma indication in EU
This article was originally published in Scrip
Executive Summary
Roche has filed its blockbuster non-Hodgkin's lymphoma (NHL) drug MabThera (rituximab) for an additional indication for the disease in the EU, maintenance treatment for previously untreated patients with advanced follicular lymphoma.